Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy
Authors
Keywords
Interleukin-12, Lung cancer, Chemotherapy, Natural Killer cells, Interferon-γ, Angiogenic
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-08-22
DOI
10.1186/s12885-016-2701-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models
- (2015) Ernst Lengyel et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cytokines reinstate NK cell–mediated cancer immunosurveillance
- (2014) Laurence Zitvogel et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
- (2014) Michele Ardolino et al. JOURNAL OF CLINICAL INVESTIGATION
- Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data
- (2014) Antonio Rossi et al. LANCET ONCOLOGY
- Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis
- (2014) H. P. Joshi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model
- (2014) Hyun-Kyung Yu et al. Translational Oncology
- Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression
- (2014) Rajesha Rupaimoole et al. Nature Communications
- Paclitaxel: new uses for an old drug
- (2014) Zheng Dong et al. Drug Design Development and Therapy
- Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model
- (2014) C.-J. Kao et al. Cancer Immunology Research
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer
- (2013) Rupal Ramakrishnan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
- (2013) Grace Dy et al. International Journal of Nanomedicine
- Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer
- (2013) Mun Sem Liew et al. Cancer Medicine
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN- Production
- (2011) A. C. Jaime-Ramirez et al. JOURNAL OF IMMUNOLOGY
- IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46
- (2010) Maya Eisenring et al. NATURE IMMUNOLOGY
- Interleukin 12 Stimulates IFN- -Mediated Inhibition of Tumor-Induced Regulatory T-Cell Proliferation and Enhances Tumor Clearance
- (2009) X. Cao et al. CANCER RESEARCH
- Paclitaxel and immune system
- (2009) Aqeel Javeed et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
- (2009) T. S. Bekaii-Saab et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started